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ABSTRACT 
An increased number of tumor-associated macrophages (TAMs) that exhibit the M2 macrophage phenotype is 
related to poorer prognosis in cancer patients. MafB is a transcription factor regulating the differentiation of mac-
rophages. However, involvement of MafB for the development of TAMs is unknown. This study was designed to 
investigate the role of MafB in a murine urethane-induced lung cancer model. Urethane was injected intraperito-
neally into wild-type and dominant-negative MafB transgenic mice. Twenty-four weeks later, mice were sacrificed 
and their lungs removed for pathological analysis. The numbers and mean areas of lung cancer were evaluated. In 
addition, the numbers of Mac-3-positive macrophages were evaluated in each tumor. The numbers and mean areas 
of lung cancer induced by urethane administration were not significantly different between wild-type and domi-
nant-negative MafB transgenic mice. The numbers of TAMs in lung cancer tissue were not significantly different 
between the two groups. MafB silencing using dominant-negative MafB did not influence the initiation and growth 
of lung cancer in mice exposed to urethane. These data suggest that MafB may not be related to the development 
of TAMs. 
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INTRODUCTION 
Lung cancer is the first and third leading 
cause of death in men and women in Japan, 
respectively. Advances involving many new 
molecularly-targeted drugs, such as epider-
mal growth factor receptor tyrosine kinase in-
hibitors and anaplastic lymphoma kinase in-
hibitors, improve the therapeutic outcome of 
lung cancer (Janne et al., 2015; Mok et al., 
2009; Shaw et al., 2013). In addition, immune 
checkpoint inhibitors, such as antibodies 
against programed cell death (PD)-1 and PD-
ligand (L)1, prolong the survival of patients 
with lung cancer (Brahmer et al., 2015; Garon 
et al., 2015; Herbst et al., 2016). Specifically, 
the binding of PD-1 on cytotoxic T cells, and 
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PD-L1 on tumor cells, reduces the cytotoxic 
activity of T cells against tumor cells. Anti-
bodies against PD-1 and PD-L1 prevent this 
immune tolerance and suppress tumor growth 
in cancer patients (Park et al., 2016). These 
inhibitors are the first immunotherapies 
showing significant clinical effects against 
lung cancer (Park et al., 2016).  
Macrophages are the most abundant im-
mune cells in the alveolar space of non-dis-
eased human lungs. Macrophages monitor the 
occurrence of tumors and eliminate neoplastic 
cells. In contrast, tumor-associated macro-
phages (TAMs) play important roles in tumor 
growth and metastasis by producing growth 
and angiogenic factors (Pollard, 2004). Thus, 
an increased number of TAMs in tumors is as-
sociated with poor prognosis in cancer pa-
tients (Kim et al., 2015; Shigeoka et al., 2013; 
Yang et al., 2015). 
We reported previously that MafB gene-
targeted mice exhibited significant changes in 
alveolar macrophage numbers, the nuclear 
compartment, cellular shape, surface marker 
expression, and phagocytic function (Sato-
Nishiwaki et al., 2013). However, the role of 
MafB in TAMs has not been investigated. In 
this study, we evaluated whether MafB si-
lencing influenced the initiation and growth 
of lung cancer induced by urethane using pre-
viously established transgenic (Tg) mice that 
specifically express dominant-negative (DN) 
MafB in macrophages under control of the 
macrophage scavenger receptor enhancer-
promoter. 
 
MATERIALS AND METHODS 
Mice 
As described previously, we established 
macrophage scavenger receptor enhancer-
promoter DN MafB transgenic (DN-MafB 
Tg) mice on the C57/BL6 background in 
which the activity of MafB was suppressed 
only in macrophages (Sato-Nishiwaki et al., 
2013). Female wild-type (WT) mice, pur-
chased from CLEA Japan (Tokyo, Japan), 
were used as controls in these experiments. 
Mice were housed in a facility with a 12/12-h 
light/dark cycle and were given free access to 
water and standard rodent chow. The rooms 
were kept free from any pathogens. Natural 
survival curves were not different between 
WT and DN-MafB mice. The study was ap-
proved by the Committee for Animal Experi-
mentation, Yamagata University School of 
Medicine, and was carried out in accordance 
with the Declaration of Helsinki. 
 
Urethane-induced lung cancer 
Female 10- to 12-week-old WT and DN-
MafB Tg mice (mean body weight: 18.8 ± 
0.9 g vs. 18.2 ± 0.8 g, P = 0.29) were injected 
intraperitoneally with 1 g/kg urethane 
(Sigma-Aldrich, St. Louis, MO, USA) dis-
solved in 0.9 % saline (Salazar-Degracia et 
al., 2016). After 24 weeks, the mice were sac-
rificed for lung fixation. Mean body weight at 
24-weeks were 23.0 ± 0.7 g in WT mice and 
22.3 ± 0.7 g in DN-MafB Tg mice (P =0.45). 
 
Histopathological examination 
Lungs were fixed by the intratracheal in-
stillation of 4 % buffered formalin at a con-
stant pressure of 25 cm H2O. After removal of 
the lungs and overnight fixation in 4 % for-
malin, paraffin-embedded lung blocks were 
prepared. These lung-sections (3 µm thick-
ness) were stained with hematoxylin and eo-
sin. Twenty-four weeks after urethane treat-
ment, proliferative lung lesions were detected 
using a light microscope. We evaluated the 
number and area of the tumors in each mouse 
in sections sliced to maximize the left and 
right lung areas. The areas were evaluated by 
Image J software (National Institutes of 
Health, Bethesda, MD, USA). There was no 
difference in the area of the sliced lungs be-
tween WT and DN-MafB mice (data not 
shown). 
 
Immunohistochemical staining 
Lung-sections were also stained with an 
anti-Mac-3 antibody (BD Biosciences, San 
Diego, CA, USA; diluted 1:100), and then 
were stained with an anti-rat IgG-HRP anti-
body (Stressgen, CA, USA; diluted 1:200). 
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Statistical analysis 
Data are expressed as means ± standard 
deviations. Differences between means were 
assessed using Welch's t-test. Survival curves 
were analyzed by the log-rank test. P values < 
0.05 were considered statistically significant. 
All statistical analyses were performed using 
JMP version 11.0 software (SAS Institute, 
Cary, NC, USA). 
 
RESULTS 
The numbers and areas of urethane- 
induced lung cancer 
Representative cross-sectional images 
of lung tissue from urethane-treated WT and 
DN-MafB Tg mice are shown in Figures 1A 
and B, respectively. Some hyperplastic and 
adenocarcinoma lesions were detected. The 
numbers of carcinoma nodules per section 
were not significantly different between WT 
and DN-MafB Tg mice (Figure 1C). The 
numbers of hyperplasic lesions per section 
were also not significantly different between 
the two groups (WT: 1.0 ± 0.46/section, DN-
MafB: 0.83 ± 0.46/section, P = 0.80). In addi-
tion, the mean tumor areas were not different 
between the two groups (Figure 1D). 
 
The numbers of TAMs in urethane-induced 
lung cancer tissue 
The numbers of TAMs in adenocarci-
noma lesions were compared between WT 
and DN-MafB Tg mice. Representative im-
ages of WT (Figure 2A) and DN-MafB Tg 
(Figure 2B) mice are shown. The numbers of 
Mac-3 positive macrophages were not signif-
icantly different between the two groups (Fig-
ure 2C). 
 
DISCUSSION 
In this study, we evaluated the impact of 
silencing MafB in macrophages on the initia-
tion and growth of lung cancer induced by 
urethane. The total tumor area after urethane 
treatment did not differ significantly between 
WT and DN-MafB Tg mice. In addition, the 
number of TAMs in the lung cancer lesions 
was not significantly different between WT 
and DN-MafB Tg mice (Figure 1). 
 
 
 
Figure 1: The numbers and mean areas of lung 
cancer after urethane treatment of wild-type (WT) 
and dominant-negative (DN)-MafB transgenic 
(Tg) mice. Representative images of adenocarci-
nomas in lung tissue from (A) WT and (B) DN-
MafB Tg mice stained with hematoxylin and eosin. 
(C) The number of carcinoma nodules per section 
from the lungs of WT and DN-MafB Tg mice was 
not significantly different between the two groups. 
(D) The mean carcinoma area per lung section 
was not significantly different between the two 
groups. Data are expressed as means ± SD (P > 
0.05). 
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Figure 2: The numbers of tumor-associated mac-
rophages in urethane-induced lung cancer of wild-
type (WT) and dominant-negative (DN)-MafB 
transgenic (Tg) mice. Representative images of 
adenocarcinomas in lung sections of (A) WT and 
(B) DN-MafB Tg mice stained with the Mac-3 an-
tibody. (C) The numbers of Mac-3-positive cells in 
urethane-induced lung cancer lesions of WT and 
DN-MafB Tg mice were not significantly different 
between the two groups. Data are expressed as 
means ± SD (P > 0.05).  
 
 
Typically, macrophages play an important 
role in innate immunity that monitors and ex-
terminates malignant neoplasms. However, 
an increase in the number of TAMs in tumors 
is related to poor prognosis in cancer patients 
(Kim et al., 2015; Shigeoka et al., 2013; Yang 
et al., 2015). These dichotomous effects arise 
because TAMs, M2-type macrophages, pro-
duce tumor growth factors such as epidermal 
growth factor, angiogenic factors such as vas-
cular endothelial growth factor, and metasta-
sis promoting factors such as matrix metallo-
proteinase (Qian and Pollard, 2010). 
In our previous studies, MafB, a regulator 
of macrophage differentiation, was shown to 
suppress apoptosis and control phagocytosis 
of macrophages (Machiya et al., 2007; Ne-
moto et al., 2017; Sato-Nishiwaki et al., 
2013). It is assumed that MafB affects macro-
phage-mediated tumor immunity by altering 
their antigen presenting ability, which may af-
fect the initiation and promotion of lung can-
cer in mouse models. In addition, peritoneal 
macrophages recovered from DN-MafB/ 
ApoE knockout mice have increased expres-
sion of M1 macrophage markers after lipopol-
ysaccharide stimulation (Hasegawa et al., 
2016). Therefore, in our gene-targeted mouse, 
it was assumed that M2 polarization in TAMs 
was insufficient. Furthermore, it was ex-
pected that the initiation and promotion of 
urethane-induced lung cancer would be sup-
pressed. However, contrary to our expecta-
tion, MafB suppression did not affect these 
processes. 
In recent years, immunotherapy has at-
tracted attention as a cancer treatment. Espe-
cially, antibodies against PD-1 and PD-L1 
have prominent effects in various malignant 
tumors (Brahmer et al., 2010; Garon et al., 
2015; Herbst et al., 2014; Topalian et al., 
2012). PD-1 is expressed on cytotoxic T lym-
phocytes and prevents the immune response 
of these cells to tumor cells by binding to PD-
L1 expressed on tumor cells. Therefore, im-
portant roles of cytotoxic T lymphocytes in 
tumor immunity have been proven clinically.  
Other studies indicate that TAMs contrib-
ute to the promotion of cancer. For example, 
there is a connection between an increase in 
the number of these cells and poor prognosis 
in many human cancers (Ahn et al., 2010; 
Steidl et al., 2010). Therefore, targeting 
TAMs may be a novel strategy for treating 
cancer. Inhibiting the recruitment of mono-
cytes to tumor tissue is one clinical tactic 
(Yang and Zhang, 2017). Antibody therapies 
targeting factors related to the accumulation 
of monocytes in tissues, such as CCL2/CCR2, 
and adhesion to vascular endothelial cells, 
such as CD11b, have also been attempted in 
animal cancer experiments and clinical stud-
ies of human cancer (Ahn et al., 2010; Ny-
wening et al., 2016). 
EXCLI Journal 2017;16:914-920 – ISSN 1611-2156 
Received: April 03, 2017, accepted: May 22, 2017, published: June 20, 2017 
 
 
918 
Inhibiting the activity of TAMs may sup-
press the progression of cancer. Development 
of antitumor drugs targeting the CSF1/CSF1 
receptor, mannose receptor CD206, and scav-
enger receptor A is proceeding (He et al., 
2012; Movahedi et al., 2012; Neyen et al., 
2013). In particular, trabectedin decreases the 
number of TAMs in tumor tissue by a selec-
tive cytotoxic effect on monocytes and mac-
rophages (Allavena et al., 2005; Germano et 
al., 2013).  
Macrophages have the potential to change 
their phenotype in the tumor microenviron-
ment. Therefore, reprogramming TAMs to an 
antitumor phenotype is another therapeutic 
approach (Yang and Zhang, 2017). Antitumor 
macrophages are expected to scavenge and 
destroy tumor cells. Pseudomonas aeruginosa 
mannose-sensitive hemagglutinin for malig-
nant pleural effusion has converted CD163+ 
TAMs to M1 macrophages. In addition, re-
programming CD163+ TAMs is a potential 
therapeutic strategy for malignant pleural ef-
fusion (Yang et al., 2015; Yang and Zhang, 
2017).  
β-Glucan is a yeast-derived polysaccha-
ride that has been suggested to differentiate 
TAMs into M1 macrophages (Chan et al., 
2009). Immunotherapy using β-glucan is al-
ready under investigation in a phase I clinical 
trial in patients with neuroblastoma (Kushner 
et al., 2014). In addition, reprogramming of 
TAMs to the M1 phenotype by manganese 
nanoparticles, CD40, and toll-like receptor 
agonists is also possible (Yang and Zhang, 
2017). 
In contrast to the positive effect of sup-
pressing TAMs in cancer treatment, the initi-
ation and growth of urethane-induced lung tu-
mors were not influenced by the expression of 
DN-MafB in macrophages. Although we con-
firmed suppression of MafB activity in bone 
marrow-derived macrophages in the gene-tar-
geted mice used in this study, MafB suppres-
sion in TAMs was not confirmed. The frac-
tion of TAMs in the lungs was too small to 
investigate the activity of MafB in this model 
(Figure 2). Because DN-MafB is expressed 
under control of the macrophage scavenger 
receptor promoter in this mouse, the expres-
sion level of DN-MafB might be insufficient 
for suppression of MafB activity in TAMs. 
The MafB knockout mouse dies soon after 
birth (Kataoka et al., 1994). Thus, alternative 
experimental approaches are not currently 
available. 
In conclusion, MafB silencing using DN-
MafB does not influence the initiation and 
growth of lung cancer in mice exposed to ure-
thane. Thus, MafB may not be related to the 
development of TAMs. 
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